Scopus BioPharma Inc. Common Stock
SCPS
SCPS was delisted on the 16th of December, 2022.
1 hedge funds and large institutions have $7.49K invested in Scopus BioPharma Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 14 closing their positions.
93% less capital invested
Capital invested by funds: $111K → $7.49K (-$103K)
93% less funds holding
Funds holding: 15 → 1 (-14)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 14
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$52K |
| 2 |
Renaissance Technologies
New York
|
-$15K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6K |
| 4 |
State Street
Boston,
Massachusetts
|
-$5K |
| 5 |
First Manhattan
New York
|
-$3K |
SCPS Hedge Fund Activity: Q4 2022 in Review
1 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Scopus BioPharma Inc. Common Stock (SCPS) for Q4 2022, worth a combined $7.49K — down 93% from $111K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of SCPS and 0 opened new positions — a net loss of 14 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Geode Capital Management, exiting entirely with an estimated $52K sold.
- 1 institutional investor held Scopus BioPharma Inc. Common Stock (SCPS) as of Q4 2022, down from 15 in Q3 2022.
- Funds reported $7.49K of Scopus BioPharma Inc. Common Stock stock for Q4 2022, down 93% quarter-over-quarter.
- 0 funds opened new Scopus BioPharma Inc. Common Stock positions in Q4 2022 and 14 closed out, a net change of -14 holders.
- The largest Scopus BioPharma Inc. Common Stock seller in Q4 2022 was Geode Capital Management, an estimated $52K sold.
Based on aggregated 13F filings for Q4 2022.